302 related articles for article (PubMed ID: 38414061)
21. Signal regulatory protein alpha blockade potentiates tumoricidal effects of macrophages on gastroenterological neoplastic cells in syngeneic immunocompetent mice.
Abe T; Tanaka Y; Piao J; Tanimine N; Oue N; Hinoi T; Garcia NV; Miyasaka M; Matozaki T; Yasui W; Ohdan H
Ann Gastroenterol Surg; 2018 Nov; 2(6):451-462. PubMed ID: 30460349
[TBL] [Abstract][Full Text] [Related]
22. Localized CD47 blockade enhances immunotherapy for murine melanoma.
Ingram JR; Blomberg OS; Sockolosky JT; Ali L; Schmidt FI; Pishesha N; Espinosa C; Dougan SK; Garcia KC; Ploegh HL; Dougan M
Proc Natl Acad Sci U S A; 2017 Sep; 114(38):10184-10189. PubMed ID: 28874561
[TBL] [Abstract][Full Text] [Related]
23. Anti-SIRP
Yanagita T; Murata Y; Tanaka D; Motegi SI; Arai E; Daniwijaya EW; Hazama D; Washio K; Saito Y; Kotani T; Ohnishi H; Oldenborg PA; Garcia NV; Miyasaka M; Ishikawa O; Kanai Y; Komori T; Matozaki T
JCI Insight; 2017 Jan; 2(1):e89140. PubMed ID: 28097229
[TBL] [Abstract][Full Text] [Related]
24. Blockade of CD47 or SIRPα: a new cancer immunotherapy.
Murata Y; Saito Y; Kotani T; Matozaki T
Expert Opin Ther Targets; 2020 Oct; 24(10):945-951. PubMed ID: 32799682
[TBL] [Abstract][Full Text] [Related]
25. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
[No Abstract] [Full Text] [Related]
26. Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis.
Zhang W; Huang Q; Xiao W; Zhao Y; Pi J; Xu H; Zhao H; Xu J; Evans CE; Jin H
Front Immunol; 2020; 11():18. PubMed ID: 32082311
[TBL] [Abstract][Full Text] [Related]
27. ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile.
Kauder SE; Kuo TC; Harrabi O; Chen A; Sangalang E; Doyle L; Rocha SS; Bollini S; Han B; Sim J; Pons J; Wan HI
PLoS One; 2018; 13(8):e0201832. PubMed ID: 30133535
[TBL] [Abstract][Full Text] [Related]
28. Macrocyclic Peptide-Mediated Blockade of the CD47-SIRPα Interaction as a Potential Cancer Immunotherapy.
Hazama D; Yin Y; Murata Y; Matsuda M; Okamoto T; Tanaka D; Terasaka N; Zhao J; Sakamoto M; Kakuchi Y; Saito Y; Kotani T; Nishimura Y; Nakagawa A; Suga H; Matozaki T
Cell Chem Biol; 2020 Sep; 27(9):1181-1191.e7. PubMed ID: 32640189
[TBL] [Abstract][Full Text] [Related]
29. Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies.
Chan H; Trout CV; Mikolon D; Adams P; Guzman R; Mavrommatis K; Abbasian M; Hadjivassiliou H; Dearth L; Fox BA; Sivakumar P; Cho H; Hariharan K
Cancer Res Commun; 2024 Feb; 4(2):505-515. PubMed ID: 38319147
[TBL] [Abstract][Full Text] [Related]
30. SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy.
Veillette A; Chen J
Trends Immunol; 2018 Mar; 39(3):173-184. PubMed ID: 29336991
[TBL] [Abstract][Full Text] [Related]
31. CD47/SIRPα pathway mediates cancer immune escape and immunotherapy.
Jia X; Yan B; Tian X; Liu Q; Jin J; Shi J; Hou Y
Int J Biol Sci; 2021; 17(13):3281-3287. PubMed ID: 34512146
[TBL] [Abstract][Full Text] [Related]
32. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
[TBL] [Abstract][Full Text] [Related]
33. Disrupting CD47-SIRPα axis alone or combined with autophagy depletion for the therapy of glioblastoma.
Zhang X; Chen W; Fan J; Wang S; Xian Z; Luan J; Li Y; Wang Y; Nan Y; Luo M; Li S; Tian W; Ju D
Carcinogenesis; 2018 May; 39(5):689-699. PubMed ID: 29538621
[TBL] [Abstract][Full Text] [Related]
34. TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding.
Petrova PS; Viller NN; Wong M; Pang X; Lin GH; Dodge K; Chai V; Chen H; Lee V; House V; Vigo NT; Jin D; Mutukura T; Charbonneau M; Truong T; Viau S; Johnson LD; Linderoth E; Sievers EL; Maleki Vareki S; Figueredo R; Pampillo M; Koropatnick J; Trudel S; Mbong N; Jin L; Wang JC; Uger RA
Clin Cancer Res; 2017 Feb; 23(4):1068-1079. PubMed ID: 27856600
[No Abstract] [Full Text] [Related]
35. Cd47-Sirpα interaction and IL-10 constrain inflammation-induced macrophage phagocytosis of healthy self-cells.
Bian Z; Shi L; Guo YL; Lv Z; Tang C; Niu S; Tremblay A; Venkataramani M; Culpepper C; Li L; Zhou Z; Mansour A; Zhang Y; Gewirtz A; Kidder K; Zen K; Liu Y
Proc Natl Acad Sci U S A; 2016 Sep; 113(37):E5434-43. PubMed ID: 27578867
[TBL] [Abstract][Full Text] [Related]
36. CD47-SIRPα Interactions Regulate Macrophage Uptake of Plasmodium falciparum-Infected Erythrocytes and Clearance of Malaria In Vivo.
Ayi K; Lu Z; Serghides L; Ho JM; Finney C; Wang JCY; Liles WC; Kain KC
Infect Immun; 2016 Jul; 84(7):2002-2011. PubMed ID: 27091932
[TBL] [Abstract][Full Text] [Related]
37. Novel SIRPα Antibodies That Induce Single-Agent Phagocytosis of Tumor Cells while Preserving T Cells.
Andrejeva G; Capoccia BJ; Hiebsch RR; Donio MJ; Darwech IM; Puro RJ; Pereira DS
J Immunol; 2021 Feb; 206(4):712-721. PubMed ID: 33431660
[TBL] [Abstract][Full Text] [Related]
38. CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity.
de Silva S; Fromm G; Shuptrine CW; Johannes K; Patel A; Yoo KJ; Huang K; Schreiber TH
Cancer Immunol Res; 2020 Feb; 8(2):230-245. PubMed ID: 31852716
[TBL] [Abstract][Full Text] [Related]
39. Targeted co-delivery of resiquimod and a SIRPα variant by liposomes to activate macrophage immune responses for tumor immunotherapy.
Jia D; Lu Y; Lv M; Wang F; Lu X; Zhu W; Wei J; Guo W; Liu R; Li G; Wang R; Li J; Yuan F
J Control Release; 2023 Aug; 360():858-871. PubMed ID: 37473808
[TBL] [Abstract][Full Text] [Related]
40. Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation.
Marquardt V; Theruvath J; Pauck D; Picard D; Qin N; Blümel L; Maue M; Bartl J; Ahmadov U; Langini M; Meyer FD; Cole A; Cruz-Cruz J; Graef CM; Wölfl M; Milde T; Witt O; Erdreich-Epstein A; Leprivier G; Kahlert U; Stefanski A; Stühler K; Keir ST; Bigner DD; Hauer J; Beez T; Knobbe-Thomsen CB; Fischer U; Felsberg J; Hansen FK; Vibhakar R; Venkatraman S; Cheshier SH; Reifenberger G; Borkhardt A; Kurz T; Remke M; Mitra S
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36639156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]